Abstract
Down-regulation of constitutive hepatic cytochrome P450 (P450) mRNAs by bacterial endotoxin (lipopolysaccharide, LPS) or other inflammatory stimuli has been documented extensively, but the contribution of transcriptional suppression to this effect is poorly understood. Here, we demonstrate that the rates of transcription of the CYP2C11, CYP3A2, and CYP2E1 genes are reduced to 20, 30, and 10% of control levels, respectively, in rat liver within 1 to 2 h of injection of LPS (1 mg/kg). The magnitude and rapidity of these effects indicate that transcriptional suppression is a primary reason for the decline in P450 mRNAs. Injection of curcumin significantly inhibited the rapid transcriptional suppression of CYP2E1, and blocked that of CYP3A2. These effects seemed to be independent of inhibition of nuclear factor-κB (NF-κB) activation by curcumin, because induction of known NF-κB-regulated genes was not attenuated. One hour after LPS injection, the DNA-binding activities of hepatocyte nuclear factor (HNF)1α, HNF3β, and HNF4α were reduced to 73, 72, and 53%, respectively, of control values. The nuclear abundances of Sp1, liver-enriched transcriptional inhibitory protein (LIP), HNF1α, and HNF3β were unchanged, whereas the abundance of HNF4α was reduced to 87% of control levels. We conclude that changes in Sp1 or LIP do not contribute significantly to the early suppression of P450 transcription in the acute phase rat liver. Although changes in DNA-binding activities of HNF1α, HNF3β, and HNF4α are too small individually to explain the observed changes in P450 transcription, the role of each factor in concert with other factors remains to be determined.
Footnotes
-
ABBREVIATIONS: P450, cytochrome P450; LPS, bacterial lipopolysaccharide; C/EPB, CCAAT/enhancer-binding protein; HNF, hepatocyte nuclear factor; TNF, tumor necrosis factor; IκB, inhibitory κB; PBS, phosphate-buffered saline; EMSA, electrophoretic mobility shift assay; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; LIP, liver-enriched transcriptional inhibitory protein.
-
This work was supported by Grant GM46897 from the National Institutes of Health. This work was presented, in part, in a symposium at the Experimental Biology 2003 meeting in San Diego, CA. Proceedings of the symposium will be summarized in an article to be submitted to Drug Metabolism and Disposition by the symposium organizer, Dr. David Riddick.
-
DOI: 10.1124/jpet.103.057174.
- Received July 16, 2003.
- Accepted September 5, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|